In-booth hands-on demo
Join us at Exhibit F.05 (Hall 6) for a one-on-one, hands-on demo to experience the world’s most advanced canaloplasty device.
Built on the tried and tested iTrack™ platform, which has been used in more than 120,000 canaloplasty procedures globally, the iTrack™ Advance combines the world’s only illuminated canaloplasty microcatheter with an easy-to-use handheld injector and custom cannula.
You’re invited to schedule your iTrack Advance™ in-booth demo.
Saturday, September 7
iTrack™ Advance: Canaloplasty Insights
Case Presentations*
The industry’s leading authorities in canaloplasty will discuss the benefits of canaloplasty as a stent-free, tissue-sparing MIGS procedure, including its ability to address all points of outflow resistance in the conventional outflow pathway. The expert panel will also share practical tips covering patient selection and surgical pearls.
10:00 a.m. – 11:00 a.m.
Nova Eye Exhibit
Faculty:
Ticiana De Francesco, MD (Brazil)
Paul Harasymowycz, MD (Canada)
12:30 p.m. — 1:00 p.m.
Nova Eye Exhibit
Sunday, Sep 8
10:30 a.m. – 11:00 a.m.
Nova Eye Exhibit
Faculty:
Mary Qiu, MD (USA)
Karl Merceica, MD (UK)
12:15 m. – 12:45 p.m.
Nova Eye Exhibit
Faculty:
Henny Beckers, MD (Germany)
Ike Ahmed, MD (US & Canada)
Gus Gazzard, MD (UK)
3:30 p.m. – 4:00 p.m.
Spanish session; English translation available
Nova Eye Exhibit
Faculty:
Prof. José María Martínez de la Casa, MD
Lyle Newball, MD
Note: *Program not affiliated with the official ESCRS schedule.
Wet Lab
iTrack Advance™ will be featured for the second time, consequently, in the MIGS Wetlab: Modern MIGS techniques not using implants, organized by Ziad Khoueir MD MSEd FEBOS-GL
Course title: MIGS without implant
Session I
Time: 10:45 a.m. — 13:45 p.m.
Mary Qiu, MD (USA)
Session II
Time: 15:00 p.m. — 18:00 p.m.
Instructor: James Murphy, MD (USA)
Canaloplasty on the podium
Canaloplasty will be featured in several presentations and posters at ESCRS 2024. See the summary below and review the ESCRS official program for more details.
Full session details can be accessed via the ESCRS program:
https://escrs-apps.m‑anage.com…
Sunday, Sept 8
08:48 — 8:54 AM
Location: Podium 3
David Lubeck (USA); Robert Noecker (USA)
Endothelial Cell Density and Loss Following Ab-Interno
Canaloplasty in patients with mild-moderate glaucoma as
compared to severe glaucoma
___________________________
09:12 — 09:18 AM
Location: Podium 3
Norbert Körber (Germany), Simon Ondrejka (Germany)
6‑Year Efficacy and Safety of iTrack Ab-interno Canaloplasty in
Primary Open-Angle Glaucoma
Monday, Sept 9
4:42 — 4:48 PM
Location: Podium 3
Nir Shoham-Hazon; David Lubeck (USA); Keith Barton (UK); Nathan Kerr (Australia)
Safety and Efficacy of Ab-interno Canaloplasty using the iTrack in Angle Closure Glaucoma: 12-month results
___________________________
5:18- 5:24 PM
Location: Podium 3
Paul J. Harasymowycz (Canada); David M. Lubeck (USA); Keith Barton (UK); Nathan M Kerr (Australia); Nir Shoham-Hazon (Canada)
Canaloplasty Effectiveness Correlated with Viscoelastic Volume Delivered
___________________________
5:30 — 5:36 PM
Location: Podium 3
Keith Barton (UK); Nathan Kerr (Australia); David Lubeck (USA); Iqbal Ike K. Ahmed (Canada); Shamil Patel(USA)
Multicenter Canaloplasty Data Registry – Outcomes of Ab-Interno Canaloplasty Across Different Glaucoma Types and Severity
___________________________
5:36 — 5:42 PM
Location: Podium 3
David Lubeck, MD (USA), Karl Mercieca (Germany); Keith Barton (UK); Nathan Kerr
(Australia)
24-Month Results of iTrack Global Data Registry to Support the Role of
Canaloplasty for Treatment of Glaucoma
___________________________
5:42 — 5:48 PM
Location: Podium 3
Karl Mercieca (Germany); David Lubeck (USA); Keith Barton (UK); Nathan Kerr (Australia)
Canaloplasty Performed with the iTrack Microcatheter to Reduce IOP in Uncontrolled Glaucoma Eyes
___________________________
5:48 — 5:54 PM
Location: Podium 3
Ahmad Aref (USA); David Lubeck (USA), Keith Barton (UK), Nathan Kerr (Australia)
Predictive Factors for ≥20% IOP Reduction in Glaucomatous Eyes Undergoing Ab-interno Canaloplasty
E‑posters
James Murphy (USA)
Efficacy and Safety Profile of Ab-Interno Canaloplasty Performed with and Without GATT in Uncontrolled Glaucoma Eyes – 24 Month Outcomes
James Murphy (USA)
Efficacy of Ab-Interno Canaloplasty Performed with or without GATT in Cases of Moderate Versus Severe Glaucoma
Simon Ondrejka (Germany)
Efficacy, and Safety of Ab-interno Canaloplasty using iTrack Advance in Primary Open-Angle Glaucoma
Jose Maria Martinez de la Casa (Spain)
Medication Burden in 3+Meds Glaucoma Eyes Following Canaloplasty via an Ab-Interno Technique Combined with Phacoemulsification
Contact Us
